Back to results
US 10,260,049 B2Granted
Attenuated reovirus
AssigneeVirocure, Inc.
InventorsManbok Kim, Randal N. Johnston
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein.
Claims8
An attenuated reovirus, comprising a reovirus genome that comprises a modification in the wild-type S1 gene, wherein the modification is selected from
- (a) a deletion of a nucleotide at nucleotide sequence position 26 of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:9 or SEQ ID NO:10;
- (b) a mutation at nucleotide sequence position 359 of SEQ ID NO:
- 9 or SEQ ID NO:10;
- (c) a mutation at nucleotide sequence position 392 of SEQ ID NO:
- 9 or SEQ ID NO:10;
- (d) a mutation at nucleotide sequence position 763 of SEQ ID NO:
- 9 or SEQ ID NO:10;
- and
- (e) a mutation at nucleotide sequence position 912 of SEQ ID NO:
- 9 or SEQ ID NO:10, wherein the mutation at nucleotide sequence position 912 causes a substitution of isoleucine to methionine in the corresponding amino acid sequence.
7 more elements
Dependencies are inferred from the claim text.